A Prospective, Randomized, Double blind, Placebo controlled clinical trial to evaluate efficacy and safety of Slimferin tablets in reducing the bodyweight in obese patients.

Vidya herbs0 个研究点目标入组 30 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Age between 18 and 50 years.
•Able to sign voluntarily informed consent.
•Obese subjects with Body mass index 30 to 40 kg/m2
•Subjects must understand risks and benefits of the protocol
•Willingness to participate in the exercise walking program
•If female, should be negative in pregnancy test. Female of child bearing potential, should agree to follow an acceptable method of birth control for the duration of the study.

•Have a history of major problems such as heart disease, thyroid disease or diabetes in the last five years.
•Any other clinically significant disorder
•Abnormal fibrinogen levels
•Non-obese (BMI <30) & morbidity obese ( >40).
•Presently using other weight loss medications, as well as stimulants, laxatives or diuretics taken solely for the purpose of weight loss
•Recent, unexplained weight loss or gain
•History of HIV positive patients
•History of hepatitis, pancreatitis, lactic acidosis or hepatomegaly with steatosis.
•History of motor weakness or peripheral sensory neuropathy
•Have orthopedic joint problems that would be barrier to physical activity such as walking.
•Are currently participating in any weight loss clinical trial.
•Women who are pregnant and nursing mothers
•People with major psychiatric illness
•Any evidence of organ dysfunction or any clinically significant deviation from the normal, in physical or clinical determinations

发起方